Login
$PCRX Congressional Trades
$36.38 -$0.04 (0.11%) Close

Congressional Trades in Pacira BioSciences, Inc.

What members of the House and Senate report owning and trading in PCRX, as filed with the House Clerk and the Senate. Every row links to the filing it came from.

Trades, last 12 months
0
by 0 members
Buys / sells
0 / 0
0 bought, 0 sold
Members reporting PCRX
0
in their latest annual report
Reported after the trade
–
median, last 12 months

Members who report holding PCRX

As filed in each member's latest annual report, in the ranges the form uses.

No sitting member's latest annual report lists PCRX.

Traded Member Trade Amount Investor Reported Source
May 6, 2021 Tom Malinowski House · D · NJ-7 Buy · Stock $1K – $15K Self Jun 23, 2021 48 days later Filing
Apr 20, 2021 Tom Malinowski House · D · NJ-7 Buy · Stock $1K – $15K Self Jun 12, 2021 53 days later Filing
Jan 25, 2021 Tom Malinowski House · D · NJ-7 Buy · Stock $1K – $15K Self Aug 26, 2021 213 days later Filing
Jan 15, 2021 Tom Malinowski House · D · NJ-7 Buy · Stock $1K – $15K Self Mar 5, 2021 49 days later Filing
Nov 2, 2020 Tom Malinowski House · D · NJ-7 Buy · Stock $1K – $15K Self Mar 5, 2021 123 days later Filing

Listed in annual reports

Transactions an annual report lists for the year it covers, apart from trade reports. Not counted in the trades above.

Traded Member Trade Amount Investor Report
May 31, 2019 Tom Malinowski Buy · Stock $15K – $50K Self 2019 Annual Report filed Aug 26, 2021

Members report each trade in a range, not an exact amount, and have up to 45 days to report it. Some filings are scans; where we could not read a scanned field with confidence it is left blank rather than guessed, and the filing link shows the original.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support